RenovoRx, Inc. (RNXT) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
333 W. SANTA CLARA STREET, SUITE 900 SAN JOSE, CA 95110 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments, including: | 6,400 | 15,192 | ||
| Cash and cash equivalents | 4,391 | 15,192 | ||
| Short-term investments | 2,049 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | (40) | |||
| Other undisclosed current assets | 865 | 1,089 | ||
| Total current assets: | 7,265 | 16,281 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 6 | |||
| Total noncurrent assets: | 6 | |||
| TOTAL ASSETS: | 7,265 | 16,287 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,102 | 938 | ||
| Accounts payable | 534 | 525 | ||
| Accrued liabilities | 568 | 413 | ||
| Total current liabilities: | 1,102 | 938 | ||
| Noncurrent Liabilities | ||||
| Total liabilities: | 1,102 | 938 | ||
| Equity | ||||
| Equity, attributable to parent | 6,163 | 15,349 | ||
| Common stock | 1 | 1 | ||
| Additional paid in capital | 37,318 | 36,632 | ||
| Accumulated other comprehensive income | 17 | |||
| Accumulated deficit | (31,173) | (21,284) | ||
| Total equity: | 6,163 | 15,349 | ||
| TOTAL LIABILITIES AND EQUITY: | 7,265 | 16,287 | ||
Income Statement (P&L) ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Operating expenses | (9,950) | (5,671) | |
| Operating loss: | (9,950) | (5,671) | |
| Nonoperating income (expense) | 61 | (653) | |
| Other nonoperating income | 4 | 119 | |
| Loss from continuing operations: | (9,889) | (6,324) | |
| Loss before gain (loss) on sale of properties: | ✕ | (6,324) | |
| Net loss available to common stockholders, diluted: | (9,889) | (6,324) | |
Comprehensive Income ($ in thousands)
| 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|
| Net loss: | (9,889) | (6,324) | |
| Other comprehensive income | 17 | ||
| Comprehensive loss, net of tax, attributable to parent: | (9,872) | (6,324) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.